News Grower

Independent coverage of AI, startups, and technology.

Ars Technica Jun 23, 2026 at 16:16 Big Tech Rising Hot

Trump may be mystery patient in odd case of 79yo getting experimental obesity drug

White House spokesperson denied it was Trump only after story was published.

Signal weather

Rising

Momentum is building quickly, so this card is a good early entry point into the topic.

By Beth Mole Original source
Trump may be mystery patient in odd case of 79yo getting experimental obesity drug

In an extremely odd case, a single 79-year-old patient was granted early access to Eli Lilly's powerful, still-experimental obesity drug retatrutide through the Food and Drug Administration's "compassionate use" program—raising immediate questions if that sole patient is President Donald Trump, according to a report by Stat News. Lilly's retatrutide is a highly anticipated next-generation obesity drug that targets GIP and glucagon hormones in addition to GLP-1. It is currently in late-stage trials to treat obesity, diabetes, sleep apnea, and other conditions. Data from a Phase 3 trial that Lilly released in May indicates that patients with obesity (but without diabetes) who took the drug for 80 weeks lost 28 percent of their weight, an amount comparable to bariatric surgery. Millions of Americans with obesity are eager to get the drug, with options being limited so far to enrolling in a clinical trial or trying to obtain it by dodgy methods. Read full article Comments

Stay on the signal

Follow Trump may be mystery patient in odd case of 79yo getting experimental obesity drug

Follow this story beyond a single article: new follow-ups, adjacent sources, and the evolving storyline.

We send a confirmation link first, then only meaningful digests.

Story map

Understand this topic fast

A quick entry into the story: why it matters now, who is involved, and where to go next for context.

Why it matters now

Fresh coverage with immediate momentum.
There are already 6 connected articles in the same storyline to continue from here.
The story keeps orbiting around Ars Technica, Experimental, and Getting Experimental, so the entity pages are the fastest way to build context.
Ars Technica already has 4 follow-up stories on the same theme.

Topic constellation

Open the live map for this story

See which entities, story threads, sources, and follow-up articles shape this story right now.

Click nodes to continue

Entity Cluster Article Hub Source

Story timeline

Continue with this story

A short sequence of events and follow-up stories to understand the arc quickly.

Jun 24, 2026 at 21:03 Ars Technica

One-two punch delivered in global operation disrupts cybercrime "assembly line"

"Operation Endgame" simultaneously disrupts two widely used crime tools.

Jun 24, 2026 at 20:28 Ars Technica

Underpromise, overdeliver? Hands-on with the $24,950 Slate auto.

It has 205 miles of bare-bones range.

Jun 24, 2026 at 20:04 Ars Technica

Experimental wine bottle tracks oxygen moving through the cork

The small bit of air in the bottle sees oxygen and other chemicals move in and out.

Jun 24, 2026 at 19:45 Ars Technica

FCC plans ID mandate that could block anonymous use of prepaid burner phones

Privacy advocates and domestic violence groups say ID mandate is a big mistake.

Jun 24, 2026 at 17:35 Ars Technica

Formula E reveals first calendar for GEN4 with lots of real race tracks

Brands Hatch, COTA, and Zandvoort will all hold an e-Prix in 2027.

Jun 23, 2026 at 16:16 Ars Technica

Trump may be mystery patient in odd case of 79yo getting experimental obesity drug

White House spokesperson denied it was Trump only after story was published.

How reliable this looks

Signal and trust for Ars Technica

This source works at a rapid pace: 100% of recent stories land in the hot window, and 0% carry visible search signal.

Trusted

Reliability

92

Freshness

100

Sources in storyline

1

Related articles

More stories that share tags, source, or category context.

More from Ars Technica

Fresh reporting and follow-up coverage from the same newsroom.

Open source page